Welcome to our dedicated page for CELLBXHEALTH PLC news (Ticker: ANPCY), a resource for investors and traders seeking the latest updates and insights on CELLBXHEALTH PLC stock.
Angle (ANPCY) operates in the medical device and liquid biopsy diagnostics sector, where news coverage focuses on clinical research publications, regulatory milestones, and commercial partnerships. The company's Parsortix platform for circulating tumor cell analysis generates announcements related to scientific validation studies, pharmaceutical collaborations, and diagnostic assay development.
News coverage for this medical device manufacturer typically includes research publications demonstrating clinical applications of CTC analysis, announcements of commercial agreements with pharmaceutical companies for drug development programs, and updates on regulatory submissions. The company's focus on cancer diagnostics means news often highlights data from clinical studies evaluating the Parsortix system's performance across different cancer types and therapeutic monitoring applications.
Key news categories for Angle include clinical research findings published in peer-reviewed journals, FDA-related announcements regarding regulatory pathways for diagnostic products, commercial contract awards from pharmaceutical partners, and trading updates on business performance. The company's position in the emerging liquid biopsy field means developments in competitive technologies and regulatory frameworks for blood-based cancer testing also influence investor interest.
This news page provides comprehensive coverage of Angle's corporate announcements, research collaborations, and industry developments affecting the liquid biopsy diagnostics market. Bookmark this page to track regulatory progress, partnership announcements, and clinical validation milestones for this medical technology company.
ANGLE plc, a leader in liquid biopsy solutions for CTCs, announced the posting of its 2023 Annual Report and Financial Statements. The report, covering the year ending December 31, 2023, is available on the company's website. Shareholders have been invited to the Annual General Meeting (AGM) scheduled for July 11, 2024, at the Surrey Technology Centre. The AGM will include a business update following formal proceedings. This announcement is significant for stakeholders tracking corporate governance and financial performance of ANGLE plc.
ANGLE announces the showcasing of its Parsortix system and assays at the European Association for Cancer Research (EACR) 2024 Annual Congress.
The company highlights two key presentations: the dual analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for genetic profiling in ovarian, breast, and lung cancer patients, and the use of its DNA Damage Response (DDR) assay to monitor treatment effectiveness in ovarian and prostate cancer patients.
The presentations demonstrate the Parsortix system's potential for personalized cancer treatment and therapeutic monitoring.
Angle PLC announced a study using their Parsortix system to analyze circulating tumor cells (CTCs) from 123 metastatic ovarian cancer patients over two and a half years. The study, the largest of its kind, involved 474 blood samples and identified two key gene markers: ERCC1, linked to worse outcomes, and ESR1, linked to better outcomes. The presence of ESR1 and absence of ERCC1 in CTCs correlated with improved progression-free survival (PFS). This research suggests that molecular characterization of CTCs could be valuable for monitoring ovarian cancer and predicting treatment responses in clinical trials.
ANGLE plc has announced a new commercial agreement with AstraZeneca to develop a Parsortix-based Androgen Receptor detection assay for prostate cancer studies, worth £550,000. The assay is expected to be completed by Q1 2025 and could provide significant revenue opportunities for the company. The Parsortix system will allow for minimally invasive assessment of the Androgen Receptor status, important in prostate cancer treatment. This agreement further validates ANGLE's technology and potential for long-term revenue growth.
FAQ
What is the current stock price of CELLBXHEALTH PLC (ANPCY)?
What is the market cap of CELLBXHEALTH PLC (ANPCY)?
